| DNA methylation cancer biomarkers: translation to the clinic WJ Locke, D Guanzon, C Ma, YJ Liew, KR Duesing, KYC Fung, JP Ross Frontiers in genetics 10, 1150, 2019 | 357 | 2019 |
| Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value C Stirzaker, E Zotenko, JZ Song, W Qu, SS Nair, WJ Locke, A Stone, ... Nature communications 6 (1), 5899, 2015 | 215 | 2015 |
| DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer A Stone, E Zotenko, WJ Locke, D Korbie, EKA Millar, R Pidsley, ... Nature communications 6 (1), 7758, 2015 | 148 | 2015 |
| Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer J Achinger-Kawecka, F Valdes-Mora, PL Luu, KA Giles, CE Caldon, W Qu, ... Nature communications 11 (1), 320, 2020 | 119 | 2020 |
| A role for GATA-2 in transition to an aggressive phenotype in prostate cancer through modulation of key androgen-regulated genes M Böhm, WJ Locke, RL Sutherland, JG Kench, SM Henshall Oncogene 28 (43), 3847-3856, 2009 | 103 | 2009 |
| Methyl-CpG-binding protein MBD2 plays a key role in maintenance and spread of DNA methylation at CpG islands and shores in cancer C Stirzaker, JZ Song, W Ng, Q Du, NJ Armstrong, WJ Locke, AL Statham, ... Oncogene 36 (10), 1328-1338, 2017 | 73 | 2017 |
| DNA methylation profile of triple negative breast cancer-specific genes comparing lymph node positive patients to lymph node negative patients A Mathe, M Wong-Brown, WJ Locke, C Stirzaker, SG Braye, JF Forbes, ... Scientific reports 6 (1), 33435, 2016 | 55 | 2016 |
| Epigenome remodelling in breast cancer: insights from an early in vitro model of carcinogenesis WJ Locke, SJ Clark Breast Cancer Research 14, 1-14, 2012 | 47 | 2012 |
| Coordinated epigenetic remodelling of transcriptional networks occurs during early breast carcinogenesis WJ Locke, E Zotenko, C Stirzaker, MD Robinson, RA Hinshelwood, ... Clinical epigenetics 7, 1-15, 2015 | 34 | 2015 |
| Clinical relevance of the transcriptional signature regulated by CDC42 in colorectal cancer F Valdés-Mora, WJ Locke, E Bandrés, D Gallego-Ortega, P Cejas, ... Oncotarget 8 (16), 26755-26770, 2017 | 20 | 2017 |
| Identification of DNA methylation biomarkers with potential to predict response to neoadjuvant chemotherapy in triple-negative breast cancer B Meyer, S Clifton, W Locke, PL Luu, Q Du, D Lam, NJ Armstrong, ... Clinical Epigenetics 13, 1-7, 2021 | 14 | 2021 |
| DNA methylation cancer biomarkers: translation to the clinic. Front Genet 10: 1150 WJ Locke, D Guanzon, C Ma, YJ Liew, KR Duesing, KYC Fung, JP Ross | 9 | 2019 |
| Epigenetic liquid biopsies for minimal residual disease, what’s around the corner? AD Johnston, JP Ross, C Ma, KYC Fung, WJ Locke Frontiers in Oncology 13, 1103797, 2023 | 5 | 2023 |
| Next-Generation Molecular Discovery: From Bottom-Up In Vivo and In Vitro Approaches to In Silico Top-Down Approaches for Therapeutics Neogenesis SE Kenny, F Antaw, WJ Locke, CB Howard, D Korbie, M Trau Life 12 (3), 363, 2022 | 1 | 2022 |
| Integrative epigenomic profiling of early breast carcinogenesis WJ Locke UNSW Sydney, 2012 | | 2012 |
Clare StirzakerGarvan Institute of Medical ResearchVerified email at garvan.org.au
